Correction: Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial (The Lancet Diabetes and Endocrinology (2017) 5(8) (597–609)(S2213858717301948)(10.1016/S2213-8587(17)30194-8));Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 8, 2017, Pages 597-609

  Petrie, John R ^a   Chaturvedi, Nishi ^b   Ford, Ian ^a   Brouwers, Martijn C G J ^h   Greenlaw, Nicola ^a   Tillin, Therese ^b   Hramiak, Irene ^c   Hughes, Alun D ^b   Jenkins, Alicia J ^d,j   Klein, Barbara E K ^e   Klein, Ronald ^e   Ooi, Teik C ^f   Rossing, Peter ^g   Stehouwer, Coen D A ^h   Sattar, Naveed ^a   Colhoun, Helen M ⁱ   Nickerson, H ^j   Lou, O ^j   Dutta, S ^j   Haw, J ^j   Anderson, C ^j   Kean, S ^j   Thomson, E ^j   Gillespie, L ^j,j   Gibb, J ^j   Greenlaw, N ^j   Keech, A ^j   March, K ^j   Williams, S ^j   Coady, E ^j   Bots, M ^j   Dreyer, J ^j   Jan, T ^j   Sheffy, K ^j   Lusky, R ^j   Peleg, S ^j   Shore, A ^j   Carty, D ^j   Donnan, P ^j   Witham, M ^j   Adler, A ^j   Lonn, E ^j   Rauchhaus, P ^j   Lindsay, R ^j   Brouwers, M ^j   Van Melckebeke, J ^j   Hamill, T ^j   Cuthbertson, L ^j   Murray, A ^j   Jolly, L ^j   Miller, E ^j   Hair, J ^j   Bell, A ^j   Carmichael, S ^j   Douglas, E ^j   Surtees, P ^j   Dinnett, E ^j   Allan, J ^j   Watson, C ^j   McLaughlin, M ^j   Brindley, G ^j   Smillie, E ^j   Motherwell, D ^j   MacDonald, S ^j   Ellis, P ^j   Stuart, D ^j   Travers, M ^j   Brearley, S ^j   Greig, L ^j   Colman, P ^j   Nankervis, A ^j   Forulanos, S ^j   West, D ^j   Vaughan, S ^j   Bjorasen, M ^j   Donlan, J ^j   Vrazas, J ^j   O'Neal, D ^j   Horsburgh, J ^j   Pater, H ^j   Kent, S ^j   Twigg, S ^j   Fulcher, G ^j   Denner, R ^j   Piotrowicz, A ^j   Januszewski, A ^j   Coy, A ^j   Paul, T ^j   McDonald, C ^j   Tereschyn, S ^j   Schmidt, N ^j   Weingert, M ^j   Heard, H ^j   Burke, S ^j   Ooi, T C ^j   Lochnan, H ^j   Sorisky, A ^j   Keely, E ^j   Malcolm, J ^j   Maranger, J ^j   Favreau, C ^j   Petherick, S ^j   Boles, K ^j   Rossing, P ^j   Hansen, T W ^j   Lund, S ^j   Hemmingsen, B ^j   Thorogood, N ^j   Green, K ^j   Robinson, T ^j   Abouglilia, K ^j   Nayman, D ^j   Miller, C ^j,j   Warren, R ^j   Aizawa, K ^j   Balasubramani, M ^j   Toth, S ^j   Harvey, K ^j   Birch, G ^j   Atkin, S ^j   Sathyapalan, T ^j   James, A ^j   Javed, Z ^j   Wilding, J ^j   Martin, B ^j   Birch, S ^j   Wilcox, A ^j   Watson, N ^j   Oliver, N ^j   Jugnee, N ^j   Rutter, M ^j   Turgut, T ^j   Shaju, A ^j   Yau, S ^j   Subin, S ^j   Walker, M ^j   Wake, D ^j   Millward, A ^j   Chong, P ^j   Hibbert, M ^j   George, J ^j   Schaper, N ^j   Pinxt, J ^j   op het Roodt, J ^j   Phillips, S ^j   Murray, L ^j   Sleigh, L ^j   Collier, A ^j   Sit, L E ^j   Allan, K ^j   Cook, J ^j   Campbell, K ^j   Hodge, L ^j   Leese, G ^j   Reekie, G ^j   Jaap, A ^j   Sudworth, A ^j   White, A ^j   more..

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ST JOSEPH S HEALTH CENTRE   (Canada)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^g STENO DIABETES CENTER   (Denmark)

^h MAASTRICHT UNIVERSITY   (Netherlands)

ⁱ UNIVERSITY OF EDINBURGH   (United Kingdom)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; ANTIDIABETIC AGENT;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMMON CAROTID ARTERY; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MORTALITY RATE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINOPATHY; SIDE EFFECT; TREATMENT DURATION; TREATMENT WITHDRAWAL; COMPLICATION; GLOMERULUS FILTRATION RATE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ATHEROSCLEROSIS; CAROTID INTIMA-MEDIA THICKNESS; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME;

EID: 85020425866     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30229-2     Document Type: Erratum

References (32)

1. Livingstone, SJ, Looker, HC, Hothersall, EJ, et al. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med, 9, 2012, e1001321.
2. Livingstone, SJ, Levin, D, Looker, HC, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008–2010. JAMA 313 (2015), 37–44.
3. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up. Diabetes Care 39 (2016), 686–693.
4. McKnight, JA, Wild, SH, Lamb, MJ, et al. Glycaemic control of type 1 diabetes in clinical practice early in the 21st century: an international comparison. Diabet Med 32 (2015), 1036–1050.
5. Conway, B, Miller, RG, Costacou, T, et al. Adiposity and mortality in type 1 diabetes. Int J Obes (Lond) 33 (2009), 796–805.
6. UK National Institute for Health and Care Excellence, Type 1 diabetes in adults: diagnosis and management. https://www.nice.org.uk/guidance/ng17?unlid=43059219201639184149 (accessed May 7, 2017).
7. American Diabetes Association. Standards of medical care in diabetes—2017. Diabetes Care 40:suppl 1 (2017), S1–S135.
8. Vella, S, Buetow, L, Royle, P, Livingstone, S, Colhoun, H, Petrie, JR, The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia 53 (2010), 809–820.
9. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998), 854–865.
10. Kooy, A, de Jager, J, Lehert, P, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 169 (2009), 616–625.
11. Peters, SA, den Ruijter, HM, Grobbee, DE, Bots, ML, Results from a carotid intima-media thickness trial as a decision tool for launching a large-scale morbidity and mortality trial. Circ Cardiovasc Imaging 6 (2013), 20–25.
12. Bots, ML, Evans, Gregory W, Riley, WA, Grobbee, DE, Carotid intima-media thickness measurements in intervention studies design options, progression rates, and sample size considerations. Stroke 34 (2003), 2985–2994.
13. Lorenz, MW, Polak, JF, Kavousi, M, et al., PROG-IMT Study Group. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet 379 (2012), 2053–2062.
14. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 348 (2003), 2294–2303.
15. Petrie, JR, Chaturvedi, N, Ford, I, et al., on behalf of the REMOVAL Trial Team. Metformin in adults with type 1 diabetes: design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): an international multicentre trial. Diabetes Obes Metab 19 (2017), 509–516.
16. Touboul, PJ, Hennerici, MG, Meairs, S, et al. Mannheim carotid intima-media thickness and plaque consensus (2004–2006–2011). An update on behalf of the advisory board of the 3rd, 4th and 5th Watching the Risk Symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis 34 (2012), 290–296.
17. Meijer, R, Grobee, DE, Bots, ML, Mannheim consensus on carotid intima-media thickness: opposite and complementary points of view. Cerebrovasc Dis 21 (2006), 415–416.
18. Polak, JF, Backlund, JY, Cleary, PA, et al., DCCT/EDIC Research Group. Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes 60 (2011), 607–613.
19. Lund, SS, Tarnow, L, Astrup, AS, et al. Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. PLoS One, 3, 2008, e3363.
20. Libman, IM, Miller, KM, DiMeglio, LA, et al., T1D Exchange Clinic Network Metformin RCT Study Group. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA 314 (2015), 2241–2250.
21. Lund, SS, Tarnow, L, Astrup, AS, et al. Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. Diabetes Obes Metab 11 (2009), 966–977.
22. Vasamsetti, SB, Karnewar, S, Kanugula, AK, Thatipalli, AR, Kumar, JM, Kotamraju, S, Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. Diabetes 64 (2015), 2028–2041.
23. de Jager, J, Kooy, A, Schalkwijk, C, et al. Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial. J Intern Med 275 (2014), 59–70.
24. Beisswenger, PJ, Methylglyoxal in diabetes: link to treatment, glycaemic control and biomarkers of complications. Biochem Soc Trans 42 (2014), 450–456.
25. Preiss, D, Lloyd, SM, Ford, I, et al. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol 2 (2014), 116–124.
26. Polak, JF, Szklo, M, Kronmal, RA, et al. The value of carotid artery plaque and intima-media thickness for incident cardiovascular disease: the multi-ethnic study of atherosclerosis. J Am Heart Assoc, 2, 2013, e000087.
27. Pitocco, D, Zaccardi, F, Tarzia, P, et al. Metformin improves endothelial function in type 1 diabetic subjects: a pilot, placebo-controlled randomized study. Diabetes Obes Metab 15 (2013), 427–431.
28. Nigam, SK, Wu, W, Bush, KT, Hoenig, MP, Blantz, RC, Bhatnagar, V, Handling of drugs, metabolites, and uremic toxins by kidney proximal tubule drug transporters. Clin J Am Soc Nephrol 10 (2015), 2039–2049.
29. Bell, S, Farran, B, McGurnaghan, S, et al. Risk of acute kidney injury and survival in patients treated with metformin: an observational cohort study. BMC Nephrol, 18, 2017, 163.
30. Donnelly, LA, Morris, AD, Pearson, ER, Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. Diabetes Obes Metab 11 (2009), 338–342.
31. Aroda, VR, Edelstein, SL, Goldberg, RB, et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab 101 (2016), 1754–1761.
32. de Jager, J, Kooy, A, Lehert, P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised, placebo controlled trial. BMJ, 340, 2010, c2181.